Inside Selling: Daniel Browne Sold 12,000 Shares of Revance Therapeutics Inc (NASDAQ:RVNC)

November 26, 2016 - By whatsonthorold

Inside Selling: Daniel Browne Sold 12,000 Shares of Revance Therapeutics Inc (NASDAQ:RVNC)

Daniel Browne Insider Sell

The CEO and President of Revance Therapeutics Inc, Daniel Browne is in the stock market news today. It was disclosed in a public document filled by Daniel Browne and submitted to the D.C. based-SEC on 25/11/2016, he sold 12,000 shares from the public company having a total value of $215,005 U.S Dollars. The unloaded shares average price was $17.9. He also unloaded 12,000 shares worth total $178,199 USD in the last month. Daniel Browne currently has rights to 208,036 shares which are about 0.75% of the California-Company’s market cap.

Revance Therapeutics Inc (NASDAQ:RVNC) Ratings Coverage

Out of 4 analysts covering Revance Therapeutics (NASDAQ:RVNC), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. $46 is the highest target while $22 is the lowest. The $34 average target is 88.89% above today’s ($18) stock price. Revance Therapeutics has been the topic of 5 analyst reports since August 22, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Guggenheim given on Monday, November 23. Brean Capital downgraded the shares of RVNC in a report on Tuesday, June 14 to “Hold” rating. Zacks downgraded the shares of RVNC in a report on Saturday, August 22 to “Hold” rating. The stock of Revance Therapeutics Inc (NASDAQ:RVNC) earned “Buy” rating by Suntrust Robinson on Tuesday, June 14. On Wednesday, March 23 the stock rating was initiated by SunTrust with “Buy”.

Insitutional Activity: The institutional sentiment decreased to 0.89 in Q2 2016. Its down 0.50, from 1.39 in 2016Q1. The ratio dropped, as 15 funds sold all Revance Therapeutics Inc shares owned while 16 reduced positions. 9 funds bought stakes while 34 increased positions. They now own 28.60 million shares or 5.50% more from 27.11 million shares in 2016Q1.

Teacher Retirement Of Texas reported 2,753 shares or 0% of all its holdings. Moreover, Rhenman Prtnrs Asset Mgmt has 0.53% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 220,000 shares. Alliancebernstein L P holds 35,300 shares or 0% of its portfolio. Polar Cap Llp holds 0.3% or 1.17M shares in its portfolio. Nq Hcif Group Limited has invested 100% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC). Citigroup holds 0% or 6,358 shares in its portfolio. Metropolitan Life Ny has invested 0% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC). Tower Rech Capital Ltd Limited Liability Company (Trc) holds 0% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC) for 191 shares. Great West Life Assurance Co Can holds 0% or 2,553 shares in its portfolio. American Int Grp Inc holds 0% of its portfolio in Revance Therapeutics Inc (NASDAQ:RVNC) for 11,769 shares. Aqr Cap Mgmt Limited Liability Co last reported 0% of its portfolio in the stock. Credit Suisse Ag last reported 0% of its portfolio in the stock. United Bank Va last reported 77,177 shares in the company. Federated Investors Pa last reported 0% of its portfolio in the stock. Moreover, Rhumbline Advisers has 0% invested in Revance Therapeutics Inc (NASDAQ:RVNC) for 19,030 shares.

Insider Transactions: Since June 13, 2016, the stock had 0 buys, and 2 selling transactions for $196,449 net activity. 12,000 shares were sold by Browne L Daniel, worth $178,199. Ruegg Curtis had sold 1,000 shares worth $18,250 on Monday, June 13.

The stock decreased 2.96% or $0.55 during the last trading session, hitting $18. About 74,829 shares traded hands. Revance Therapeutics Inc (NASDAQ:RVNC) has declined 10.76% since April 25, 2016 and is downtrending. It has underperformed by 16.77% the S&P500.

Revance Therapeutics, Inc. is a biotechnology company. The company has a market cap of $524.58 million. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. It currently has negative earnings. The Company’s TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel , or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable.

According to Zacks Investment Research, “Revance is a Silicon Valley-based biotechnology company. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revance’s initial focus is on developing daxibotulinumtoxinA, the company’s highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.”

Analysts await Revance Therapeutics Inc (NASDAQ:RVNC) to report earnings on March, 1. They expect $-0.88 earnings per share, down 6.02% or $0.05 from last year’s $-0.83 per share. After $-0.64 actual earnings per share reported by Revance Therapeutics Inc for the previous quarter, Wall Street now forecasts 37.50% negative EPS growth.

Another recent and important Revance Therapeutics Inc (NASDAQ:RVNC) news was published by Fool.com which published an article titled: “Why Revance Therapeutics Is Crashing 23% Today” on June 14, 2016.

RVNC Company Profile

Revance Therapeutics, Inc., incorporated on August 10, 1999, is a biotechnology company. The Firm is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. The Company’s TransMTS technology enables delivery of botulinum toxin type A through approximately two investigational drug product candidates, DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. The Company’s botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. First, its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Second, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>